Expression of the DF3-P epitope in human ovarian carcinomas.
Expression of the DF3-P epitope in human ovarian carcinomas.
复制标题
DF3-P 表位在人卵巢癌中的表达。
作者：
Keiko Ichige;L. Perey;C. Vogel;F. Buchegger;D. Kufe
最近的研究描述了一种名为 DF3-P 的 mAb 的生成，它与 DF3/MUC1 粘蛋白样糖蛋白的糖基化不足的前体发生反应。目前的工作表明，mAb DF3-P 识别的表位由源自人上皮性卵巢癌而非畸胎癌的细胞系表达。单细胞悬液的间接免疫荧光分析支持 DF3-P 表位在卵巢癌表面的表达。对室载玻片的免疫荧光研究进一步证明 mAb DF3-P 反应细胞呈簇状存在。我们还证明 125I 标记的 mAb DF3-P 选择性定位于无胸腺小鼠的人卵巢癌异种移植物。对于植入的 CAOV-3 和 OVCAR-3 肿瘤，注射 125 I 剂量/g 组织的百分比范围在 10% 至 17% 之间。最后，免疫过氧化物酶染色研究的结果表明，在福尔马林固定的卵巢肿瘤切片中可检测到 DF3-P 表位，并且 mAb DF3-P 与正常周围组织几乎没有反应性。 DF3-P 表位的选择性表达可能可用作卵巢癌放射成像或免疫治疗方法的靶标。
Recent studies have described the generation of a mAb, designated DF3-P, which reacts with underglycosylated precursors of the DF3/MUC1 mucin-like glycoprotein. The present work demonstrates that the epitope recognized by mAb DF3-P is expressed by cell lines derived from human epithelial ovarian carcinomas and not a teratocarcinoma. Indirect immunofluorescence assays of single-cell suspensions support expression of the DF3-P epitope on the surface of ovarian carcinomas. Immunofluorescence studies on chamber slides further demonstrate that the mAb DF3-P-reactive cells are present in clusters. We also demonstrate that 125I-labeled mAb DF3-P selectively localizes to human ovarian carcinoma xenografts in athymic mice. The percentage of injected 125I dose/g tissue ranged between 10 and 17% for implanted CAOV-3 and OVCAR-3 tumors. Finally, the results of immunoperoxidase staining studies demonstrate that the DF3-P epitope is detectable in formalin-fixed sections of ovarian tumors and that mAb DF3-P exhibits little if any reactivity with normal surrounding tissues. Selective expression of the DF3-P epitope may be useful as a target for radioimaging or immunotherapeutic approaches to ovarian cancer.
DOI：
10.1073/pnas.85.7.2320
发表时间：
1988-04-01
影响因子：
11.1
作者：
SIDDIQUI, J;ABE, M;KUFE, D
通讯作者：
KUFE, D
来自乳腺癌患者的细胞毒性 T 淋巴细胞识别恶性细胞优先表达的粘蛋白分子蛋白核心上存在的表位。
影响因子：
11.2
作者：
Jerome,KR;Barnd,DL;Bendt,KM;Boyer,CM;Taylor-Papadimitriou,J;McKenzie,IF;BastJr,RC;Finn,OJ
通讯作者：
Finn,OJ
单克隆抗体 F36/22 与人卵巢腺癌的反应性。
影响因子：
11.2
作者：
Croghan,GA;Wingate,MB;Gamarra,M;Johnson,E;Chu,TM;Allen,H;Valenzuela,L;Tsukada,Y;Papsidero,LD
通讯作者：
Papsidero,LD